Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function

Lanzhou Li1,2, Chenfei Zhao1, Fange Kong1, Yi-Cong Li1, Chunxia Wang1, Shanshan Chen2, Hor-Yue Tan3*, Yang Liu1* and Di Wang1,2*

1Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, Jilin Agricultural University, Changchun, China, 2School of Life Sciences, Jilin University, Changchun, China, 3Centre for Chinese Herbal Medicine Drug Development, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

Calf thymus polypeptide (CTP), with a molecular mass of <10 kDa, is prepared from the thymus of less than 30-day-old newborn cattle. In the present study, the inhibitory function of CTP in colorectal cancer (CRC) was investigated in B6/JGpt-Apcem1Cin(MinC)/Gpt (ApcMin+/+) mice. CTP hampered tumor development and enhanced the ratio of CD3ε−NK1.1+ cells by 113.0% and CD3ε+CD28+ cells by 84.7% in the peripheral blood of ApcMin+/+ mice. CTP improved the richness, diversity, and evenness of the intestinal microbiota of ApcMin+/+ mice, particularly by regulating the abundance of immune-related microorganisms. CTP effectively regulated the expression of immune-related cytokines, such as interleukin (IL)-2 (15.19% increment), IL-12 (17.47% increment), and transforming growth factor (TGF)-β (11.19% reduction). Additionally, it enhanced the levels of CD4 and CD8, as well as the ratio of helper T lymphocytes (Th1/Th2) in the spleen and tumors of ApcMin+/+ mice. In CTP-treated mice, reduced levels of programmed death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), activated nuclear factor of activated T cells 1 (NFAT1), and nuclear factor κB (NF-κB) p65 signaling were noted. Collectively, the anti-CRC effect of CTP is related to the modulation of intestinal microbiota-mediated immune function, which provides a reference for CTP as a therapeutic drug or a combination drug used in CRC treatment in a clinical setting.

Keywords: calf thymus polypeptide, colorectal cancer, intestinal microbiota, T cells, NK cells, interleukin-2

1 INTRODUCTION

Colorectal cancer (CRC) is a disease prevalent globally, resulting in a serious health burden, which is the fourth most common cancer (age-standardized prevalence: 19.7/100,000) and the third cause of cancer deaths (age-standardized mortality: 9/100,000) worldwide (Schliemann et al., 2021). Most CRC patients have no significant genetic correlation, and diet, age, and living habits may be key driving factors for the occurrence and development of CRC (Wang et al., 2018; Schulpen and van den Brandt, 2020). According to the location and progression of the tumor, standard treatments for CRC include surgery,
chemotherapy, radiotherapy, and combined treatment. It is almost impossible to completely eliminate cancer cells using surgery alone (Miller et al., 2019). The 5-year survival rates following surgical removal of CRC tumors are 91.1% (localized), 71.7% (regional), and 13.3% (distant) in the United States, respectively (Siegel et al., 2017). More than 60% of CRC regional patients received further treatment with adjuvant chemotherapy and/or radiotherapy (Miller et al., 2019). Even with neoadjuvant (Chemo) chemoradiotherapy, local tumor recurrence occurs in 10% of patients with CRC (Ogura et al., 2019). Therefore, it is crucial to develop alternative, safe, and efficacious treatment strategies for patients with CRC.

Immune responses recognize cancer cells and potentially eradicate tumors (Gajewski et al., 2013). Activated T cells promote immune response by secreting interferon (IFN)-γ (Mandai et al., 2016), or directly killing tumor cells by cytotoxicity (Su et al., 2018). Tregs inhibit the immune effect of T cells through the programmed death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) combination (Khaja et al., 2017). PD-1, expressed on the surface of T cells, binds to Tregs or tumor cells through its ligand PD-L1, resulting in a weakened immune response (Kollmann et al., 2017; Langhans et al., 2019). Accordingly, PD-1 and PD-L1 antibodies show dynamic and lasting tumor regression effects in a clinical setting (Sunshine and Taube, 2015). Direct administration of interleukin (IL)-2 or adoptive cell transfer with cecum and anus was carefully dissected; cecum contents were collected and weighed, and organ coefficients were calculated as follows: CTP on CRC in B6/J-Gpt-Apcem1Cin(MinC)/Gpt mice by regulating intestinal microbiota and their immune response.

2 MATERIALS AND METHODS

2.1 CTP Preparation

CTP, a multi-component peptide, was prepared by hydrolyzing and ultrafiltration from less than 30-day-old newborn cattle thymus (provided by Jilin Connell Pharmaceutical Co., Ltd., Jilin, China) similar to our previous study (Li et al., 2020). More than 60% of CRC patients received further treatment with adjuvant chemotherapy and/or radiotherapy (Miller et al., 2019). Therefore, it is crucial to develop alternative, safe, and efficacious treatment strategies for patients with CRC.

2.2 Protocol for Animal Experimentation and Drug Administration

Eight-week-old male B6/J-Gpt-Apcem1Cin(MinC)/Gpt (ApcMin+/−) mice (genotype: APC; genetic background: C57BL/6J-Gpt; heterozygous) (25 ± 1 g, specific pathogen-free (SPF) grade, SCXK (SU) 2018–0009), purchased from GemPharmatech Co., Ltd. (Jiangsu, China), were housed in a controlled environment at 23 ± 1°C and humidity 55 ± 5% under a 12/12-h light/dark cycle (lights on from 7:00 a.m. to 7:00 p.m.). Sterilized high-sugar and high-fat diets (D12492; 60% kcal fat, 20% kcal protein, and 20% kcal carbohydrate; Xiao Shu You Tai Biotechnology Co., Ltd., Beijing, China) and water were provided ad libitum. The experimental protocol complied with ARRIVE guidelines and was approved by the Institution Animal Ethics Committee of Jilin University (No. SY201910003).

After 1 week of adaptive feeding, 18 male mice were randomly divided into two groups and intraperitoneally (i.p.) received 0 mg/kg (vehicle-treated mice) once per day for 56 days; body weights were recorded on the days 1, 14, 28, 42, and 56. Blood samples were collected from the caudal veins of the mice 1 h after the last administration. The mice were then euthanized by CO2 inhalation, and their colorectum with cecum and anus was carefully dissected; cecum contents were collected under aseptic conditions and stored at −80°C for intestinal microbiota analysis. After cleaning the colorectum with normal saline, its weight and length were analyzed; the colorectal index was calculated as follows:

\[
\text{Colorectal index (g/m)} = \frac{\text{colorectal weight (g)}}{\text{colorectal length (m)}}.
\]

The heart, liver, spleen, lung, thymus, and kidney specimens of each mouse were collected and weighed, and organ coefficients were calculated as follows:

\[
\text{Organ index (mg/g)} = \frac{\text{organ weight (mg)}}{\text{body weight (g)}}.
\]

2.3 Peripheral Blood Component Assay

Three peripheral blood samples from each group were randomly selected, and white blood cells (WBC), lymphocytes (LYM),
monocytes (MON), granulocytes (GRA), red blood cells (RBC), mean corpuscular volume (MCV), platelets (PLT), and mean platelet volume (MPV) were analyzed using a fully automated blood analyzer (Drew Scientific Inc., Oxford, CT, United States).

2.4 Measurement of NK and T Cells in the Peripheral Blood Using Flow Cytometry

The non-nucleated cells of six peripheral blood samples (randomly selected) from each group were removed using a red blood cell lysis buffer (00-4333-57), and residual cells were re-suspended in cell staining buffer (00-4222-26) to adjust the cell concentration to $1 \times 10^7$/ml. A 100 μl cell suspension from each sample was coated with NK cells (CD3−NK1.1+) with fluorescein isothiocyanate (FITC)-conjugated anti-CD3e monoclonal antibody (11-0031-82) and allophycocyanin-conjugated anti-NK1.1 antibody (17-5941-82) or coated for activated T cells (CD3e+CD28+) with FITC-conjugated anti-CD3e monoclonal antibody (11-0031-82) and allophycocyanin-conjugated anti-CD28 antibody (17-0281-82) for 15 min at 25 ± 1°C. FITC-conjugated anti-Armenian hamster IgG (11-4888-81), allophycocyanin-conjugated anti-mouse IgG2a (17-4724-81), and allophycocyanin-conjugated anti-Syrian hamster IgG (17-4914-81) were used as the isotype controls. The cells were then analyzed using a CytoFLEX flow cytometer according to the manufacturer’s instructions. All antibodies and buffers were obtained from eBioscience (San Diego, CA, United States).
TABLE 1 | Effect of CTP on the body weight and organ index of ApcMin/+ mice.

|               | 0 mg/kg   | 6.75 mg/kg |
|---------------|-----------|------------|
| Body weight (g) |           |            |
| 1st day       | 26.9±1.6  | 26.2±1.2   |
| 14th day      | 28.1±1.9  | 28.3±1.9   |
| 28th day      | 28±3.3    | 27.8±2.7   |
| 42nd day      | 25.6±2.5  | 26.6±3.3   |
| 56th day      | 23.2±3.2  | 22.0±2.4   |
| Organ index (mg/g) |        |            |
| Heart         | 9.4±1.6   | 10.1±2.4   |
| Liver         | 50.8±6.4  | 53.9±6.8   |
| Spleen        | 11.4±4.1  | 16.2±3.4   |
| Lung          | 8.1±2.2   | 7.6±0.7    |
| Kidney        | 12.7±0.5  | 13±0.9     |
| Thymus        | 0.7±0.3   | 0.6±0.2    |

Data are presented as mean ± S.D. \((n=9)\) and analyzed via a one-way ANOVA test. *\(p<0.05\) vs. vehicle-treated mice.

2.5 Histopathological Analysis and Immunohistochemical Examination

The colorectum, heart, liver, spleen, kidney, and lung specimens collected from ApcMin/+ mice were fixed in 4% paraformaldehyde for 48 h. Samples were embedded in paraffin, sliced into 5 µm sections, and stained with hematoxylin and eosin (H&E), as described in a previous study (Elsherbiny et al., 2017).

Other sections of the colorectum (especially the colorectal tumor portion) and spleen were blocked with 5% bovine serum albumin (Gen-view Scientific, Galveston, TX, United States) for 4 h and incubated with primary antibodies including CD4 (25229S, 1:200 dilution) and CD8 (98941S, 1:800 dilution) for 4 h and then incubated with primary antibodies including CD4 (PA5-95560, 1:1000 dilution) and IL-4 (PA5-25165, 1:1000 dilution) (Invitrogen, Carlsbad, CA, United States) at 4°C overnight, followed by incubation with horseradish peroxidase (HRP)-labeled secondary antibodies (E-AB-1003 or E-AB-1001) (Elabscience, Wuhan, China) at 4°C for 2 h.

Color development was performed using the Metal Enhan DAB Substrate Kit (34,065, Thermofisher, Carlsbad, CA, United States), and hematoxylin was used for counterstaining. All the slides were observed under a light microscope (Olympus Corporation, Tokyo, Japan).

2.6 Intestinal Microbiota Analysis

The contents from four cecum samples collected from vehicle-treated mice were selected randomly for 16S RNA gene analysis of the intestinal microbiota. The total mass of microbial DNA ranging from 1.2 to 20 ng isolated from each cecum content using the OMEGA Soil DNA Kit (M5635-02) (Omega Bio-Tek, Norcross, GA, United States) was stored at -20°C. The forward primer 338F (5'-ACTCCTACGGGAGGCAGCA-3') and reverse primer 806R (5'-GGACTACHVGGGTWTCTAAT-3') were used to amplify the V3–V4 regions of the bacterial 16S rRNA gene by PCR amplification. The amplicons were pooled in equal amounts, and pair-end 2 × 250 bp sequencing was performed using the Illumina MiSeq platform with a MiSeq Reagent Kit v3 at Shanghai Personal Biotechnology Co., Ltd. (Shanghai, China). The bacteria sequences were uploaded to the NCBI Sequence Read Archive with the accession number PRJNA796779 (https://www.ncbi.nlm.nih.gov/sra/PRJNA796779). This analysis was performed as described in our previous study (Jiang et al., 2021).

2.7 Assay of Cytokines in the Serum and Colon of ApcMin/+ Mice

The levels of IL-1β (FY2040-A), IL-2 (FY2698-A), IL-6 (FY2163-A), IL-8 (FY2123-A), IL-10 (FY2176-A), IL-12 (FY2105-A), immunoglobulin (Ig) A (FY2055-A), IgG (FY2057-A), toll-like receptor (TLR) 4 (FY2816-A), TLR5 (FY3013-A), and transforming growth factor (TGF)-β (FY2686-A) (Jiangsu Feiya Biological Technology Co., Ltd., Jiangsu, China) and IL-4 (EK0405) (Wuhan Boster Biological Engineering Co., Ltd., China, Wuhan, China) in the serum and colon were determined using enzyme-linked immunosorbent assay (ELISA) kits in accordance with the manufacturer’s instructions in ApcMin/+ mice.

2.8 Western Blot

The spleen and colorectal tumor tissues collected from ApcMin/+ mice were lysed with radioimmunoprecipitation assay lysis buffer containing a 1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, United States) and 2% phenylmethylsulfonyl fluoride (Sigma-Aldrich, St. Louis, MO, United States). The protein content was analyzed using a bicinchoninic acid protein assay kit (Merck, Darmstadt, Germany). The obtained proteins (40 µg) were separated by 10%–12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto 0.45-µm polyvinylidene difluoride membranes (Merck, Darmstadt, Germany).

The membranes were blocked with 5% bovine serum albumin (Gen-view Scientific, Galveston, TX, United States) at 4°C for 4 h and then incubated with primary antibodies including CD4 (bs-0647R, 1:1000 dilution), CD8 (bs-0648R, 1:1000 dilution), IL-1β (bs-1867R, 1:1000 dilution), IL-2 (bs-4914R, 1:1000 dilution), cytokotoxic T lymphocyte associated antigen 4 (CTLA4) (bs-10006R, 1:1000 dilution) (Bioss, Beijing, China), and IL-2 (bs-1000156, 1:2000 dilution) (Abcam, Cambridge, MA, United States), inhibitor of nuclear factor kappa-B kinase α/β (IKKα/β) (A2062, 1:1000 dilution), P-IKKα/β (AP0981, 1:1000 dilution), nuclear Factor kB (NF-kB) p65 (A19653, 1:1000 dilution), P-NF-kB p65 (AP0475, 1:500 dilution), IL-2 (A16317, 1:1000 dilution) (Abclonal, Wuhan, China), phosphatidylinositol 3-kinase 3-kinase (PI3K) (AP0891, 1:1000 dilution), protein kinase B (AKT) (ab108266, 1:2000 dilution) (Abcam, Cambridge, MA, United States), phosphatidylidyinositol 3-kinase (PI3K) (4263, 1:1000 dilution), P-PI3K (4228, 1:1000 dilution), phosphor (P)-AKT (ab108266, 1:2000 dilution) (Abcam, Cambridge, MA, United States), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (AB961, 1:800 dilution) (Abcam, Cambridge, MA, United States).
1003) (Elabscience, Wuhan, China) at 4°C for 4 h. Protein bands were developed using an enhanced chemiluminescence detection kit (Merck, Darmstadt, Germany) and visualized using the BioSpectrum 600 imaging system. The pixel density was measured using ImageJ software (National Institutes of Health, Bethesda, MD, United States).

2.9 Statistical Analysis
All values are expressed as mean ± standard deviation (S.D.). A one-way analysis of variance (ANOVA) was performed to detect the statistical significance using SPSS 19.0.0 software (IBM Corporation, Armonk, NY, United States). A p-value < 0.05 was considered statistically significant.
TABLE 2 | Dominant nodes based on the LEfSe analysis of intestinal microbiota in Apc\textsuperscript{Min/+} mice.

| Group          | Taxa                                              | Abundance (log\textsubscript{2}) | LDA score |
|----------------|---------------------------------------------------|----------------------------------|-----------|
| 0 mg/kg        | Bacteria.firmicutes.erysipelotrichi               | 4.681*                           | 4.333     |
|                | Bacteria.firmicutes.erysipelotrichi.erysipelotrichiales | 4.694*                           | 4.339     |
|                | Bacteria.firmicutes.erysipelotrichi.erysipelotrichiales.erysipelotrichaceae.allobaculum | 4.694*                           | 4.338     |
|                | Bacteria.actinobacteria.coriorbacteria.coriorbacterales.coriorbacteraeae | 4.114*                           | 3.876     |
|                | Bacteria.proteobacteria.deltaproteobacteria.desulfobionibacteriaceae | 5.545*                           | 4.889     |
|                | Bacteria.proteobacteria.desulfobionibacteriaceae.deltaproteobacteria.desulfobionibacteriaceae | 5.531*                           | 4.888     |
| 6.75 mg/kg     | Bacteria.cyanobacteria                           | 2.968*                           | 4.074     |
|                | Bacteria.cyanobacteria.4C0d_2,YS2                | 2.968*                           | 4.059     |
|                | Bacteria.cyanobacteria.4C0d_2                    | 2.968*                           | 4.063     |
|                | Bacteria.firmicutes.clostridia                  | 5.773#                           | 5.017     |
|                | Bacteria.firmicutes.clostridia.clostridiales.lachnospiraceae.coprococcus | 4.011*                           | 3.979     |
|                | Bacteria.firmicutes.clostridia.clostridiales.lachnospiraceae.ruminococcus    | 4.425*                           | 3.856     |
|                | Bacteria.firmicutes.clostridia.clostridiales.clostridium   | 2.704*                           | 4.646     |
|                | Bacteria.bacteroidetes.bacteroidia.bacteroidiales.prevotellaceae    | 2.408*                           | 4.169     |
|                | Bacteria.bacteroidetes.bacteroidia.bacteroidiales._paraprevotellaceae._prevotella_ | 4.020**                          | 3.790     |

Data are presented as mean and analyzed via a Wilcoxon test (n = 5 for the vehicle-treated group and n = 4 for the CTP-treated group). The advantaged group, logarithm abundance of dominant nodes, and LDA scores are provided. *p < 0.05 vs. CTP-treated mice; # p < 0.05 and ## p < 0.01 vs. vehicle-treated mice.

3 RESULTS

3.1 CTP Suppressed CRC Growth in Apc\textsuperscript{Min/+} Mice

In the colorectum of Apc\textsuperscript{Min/+} mice, an obvious colorectal tumor formation was noted. In contrast, CTP strongly suppressed the number and size of colorectal tumors (Figure 1A) and decreased the colorectal index by 20.98% (p < 0.05) (Figure 1B) without affecting the body weight and organ indices, except for the spleen (42.49% increment vs. vehicle-treated mice) (Table 1). The development of colorectal proliferative tissue in Apc\textsuperscript{Min/+} mice was significantly inhibited by CTP, indicating a more normal morphology of intestinal epithelial cells and a more obvious infiltration of immune cells in CTP-treated mice than in vehicle-treated mice (Figure 1E). No significant changes in the pathological sections of the heart, liver, spleen, and lungs were noted in either vehicle- or CTP-treated Apc\textsuperscript{Min/+} mice (Supplementary Figure S1).

Compared with vehicle-treated Apc\textsuperscript{Min/+} mice, CTP-treated mice showed an increase in the numbers of WBC, LYM, MON, GRA, and PLT in the peripheral blood (Supplementary Table S1). CD3\textsuperscript{+} NK1.1\textsuperscript{+} and CD3\textsuperscript{+}CD28\textsuperscript{+} represent NK cells and activated T cells, respectively, which reflect the levels of cytotoxic immune response (Yan et al., 2018). CTP treatment significantly increased the circulating populations of CD3\textsuperscript{+} NK1.1\textsuperscript{+} cells from 0.56% to 1.20% (p < 0.001) (Figure 1C) and CD3\textsuperscript{+}CD28\textsuperscript{+} cells from 2.50% to 4.61% (p < 0.01) (Figure 1D) in Apc\textsuperscript{Min/+} mice, as analyzed by flow cytometry. These results showed that CTP suppressed CRC growth primarily by improving the cytotoxic immune response in Apc\textsuperscript{Min/+} mice.

3.2 CTP Regulated the Intestinal Microbiota in Apc\textsuperscript{Min/+} Mice

Intestinal microbiota can influence the occurrence and development of CRC (Lenoir et al., 2016; Yamaoka et al., 2018). The Venn result showed that the same number of amplicon sequence variants (ASVs) between the vehicle-treated and CTP-treated Apc\textsuperscript{Min/+} mice was 1,560, proving that CTP could alter the microbiota composition of the cecal contents (Figure 2A). The Krona species composition map intuitively showed the differences in each level between groups (Supplementary Figure S2). The UniFrac NMDS result failed to distinguish between the two tested groups (Figure 2B). Compared with vehicle-treated Apc\textsuperscript{Min/+} mice, in CTP-treated mice, there was a significant increase in five indices (Chao1, Observed species, Simpson, Shannon, and Pielou’s e) (p < 0.05) (Figure 2C); consequently, this delineated the regulation of the richness, diversity, and evenness of the intestinal microbiota by CTP. Based on the abundance, CTP caused over a 50% increase in the levels of unidentified_Clostridiales, Lachnospiraceae [Ruminococcus], and over a 50% reduction in the levels of Desulfovibrioaceae, Allobaculum, Lactobacillus, unidentified_Coriobacteraeae on the genus level heat map (Figure 2D). The seed network map of the top 50 dominant ASVs showed that ASVs with complex correlations between nodes were weakly affected by CTP, and ASVs with simple correlations between nodes changed more significantly (Figure 2E). Therefore, CTP may only affect the abundance of specific functional microorganisms.

A linear discriminant analysis effect size (LEfSe) analysis was used to analyze the different biomarkers at all classification levels of the cecal contents (Supplementary Table S2). There were 15 significantly different nodes between vehicle-treated and CTP-treated mice (p < 0.05, LDA >2) (Table 2). Erysipelotrichi (class level), Coriobacteraeae (family level), Desulfovibrioaceae (order level), and part subordinate nodes demonstrated a high abundance in the cecal contents of vehicle-treated Apc\textsuperscript{Min/+} mice, which decreased significantly after CTP treatment. Cyanobacteria (phyllum level), Clostridia (class level), Prevotellaceae (family level), and part subordinate nodes demonstrated a high abundance in the cecal contents of the Apc\textsuperscript{Min/+} mice treated with 6.75 mg/kg CTP (p < 0.05, LDA >2) (Table 2).
3.3 Effect of CTP on Cytokines Levels of Serum and Colorectum in ApcMin/+ Mice

The levels of immune-related cytokines were analyzed to evaluate the immunomodulatory effect of CTP in ApcMin/+ mice. Compared with the vehicle-treated ApcMin/+ mice, CTP treatment significantly enhanced the serum levels of IL-1β (19.50%) (p < 0.05) (Figure 3A), IL-2 (15.19%) (p < 0.05) (Figure 3B), IL-6 (13.29%) (p < 0.05) (Figure 3D), IL-8 (27.95%) (p < 0.05) (Figure 3E), IL-12 (17.47%) (p < 0.05) (Figure 3G), IgA (21.70%) (p < 0.05) (Figure 3H), IgG (20.42%) (p < 0.01) (Figure 3I), TLR4 (10.82%) (p < 0.05) (Figure 3J), TLR5 (35.22%) (p < 0.001) (Figure 3K), and enhanced colorectum levels of IL-1β (62.29%) (p < 0.01) (Figure 3A), IL-2 (35.30%) (p < 0.05) (Figure 3B), IL-6 (20.07%) (p < 0.05) (Figure 3D), IL-8 (33.24%) (p < 0.01) (Figure 3E), IL-12 (32.48%) (p < 0.05) (Figure 3G), IgA (37.18%) (p < 0.01) (Figure 3H), IgG (33.82%) (p < 0.05) (Figure 3I), and TLR5 (94.21%) (p < 0.01) (Figure 3K).

Moreover, CTP reduced the serum levels of IL-10 (11.35%) (p < 0.05) (Figure 3F), and TGF-β (11.19%) (p < 0.001) (Figure 3L), and reduced the colon levels of IL-4 (15.01%) (p < 0.05) (Figure 3C), IL-10 (19.28%) (p < 0.05) (Figure 3F), and TGF-β (24.84%) (p < 0.05) (Figure 3L) in ApcMin/+ mice.

CTP induced an immunomodulatory effect in ApcMin/+ mice.

3.4 CTP Regulated the Immune Function via IL-2-Associated Signaling Pathway in ApcMin/+ Mice

Immunohistochemistry and Western blot analysis were used to explore the relationship between the suppressive effect of CTP on CRC and immune regulation in ApcMin/+ mice. CTP significantly increased the levels of CD4 and CD8, enhanced the expression of IFN-γ, and suppressed the levels of IL-4 in the spleen (p < 0.05) (Figures 4A,C) and colorectal tumors (p < 0.05) (Figures 4B,D).
of Apc\textsuperscript{Min/+} mice, suggesting the increased number of CD8\textsuperscript{+} and CD4\textsuperscript{+} cells and the increased proportion of helper T lymphocytes (Th)1/Th2 in CTP-treated Apc\textsuperscript{Min/+} mice.

According to the results of the Western blot, CTP significantly increased the levels of CD4, CD8, and IL-2, and reduced the levels of CTLA4 and PD-L1 in the tumor (Figure 5A), and CTLA4 and PD-1 in the spleen (Figure 5B) of Apc\textsuperscript{Min/+} mice; this underscored the pivotal role of IL-2 in the immune response. Furthermore, CTP significantly increased the expression levels of calcineurin A, NFAT1, P-Pi3K, P-AKT, P-IKKa/β, and P-NF-κB p65 in the spleen of Apc\textsuperscript{Min/+} mice (Figure 5C), indicating the activation of the NFAT1 and NF-κB p65 pathways.

4 DISCUSSION

In the present study, the anti-CRC effect of CTP was systematically confirmed in the Apc\textsuperscript{Min/+} mice model, which was achieved by regulating the composition of the intestinal microbiota and enhancing the immune cytolytic activity of both NK cells and cytotoxic T cells.

CTP effectively limited the development of CRC and modulated the abundance of the intestinal microbiota in Apc\textsuperscript{Min/+} mice. The total number of microbes may reach 100 trillion in the adult human intestine (Barengolts, 2013), which has been shown to play specific roles in various diseases. Accordingly, secondary metabolites of Clostridia can effectively regulate immunity and limit chronic inflammation, thereby impeding the occurrence and development of CRC (Reichardt et al., 2014; Zhang Z et al., 2019). Allobaculum is considered an indicator of defective immune responses in CD45-deficient mice (Dimitriu et al., 2013). Desulfovibronales is an important source of cytotoxic compounds, such as toxins and hydrogen sulfide in the intestine, and causes various diseases (Loubinoux et al., 2000; Sawin et al., 2015). Furthermore, its reduced abundance helps to inhibit inflammation-associated
CRC (Zhang H et al., 2019). CTP significantly increased the abundance of Clostridia, and reduced the abundance of Allobaculum and Desulfovibrionales, suggesting that the anti-CRC effect of CTP is partially related to its modulation of the intestinal microbiota, which may influence immune regulation.

The aggregation of T cells in the tumor tissue reflects an improvement in the prognosis of patients with CRC (Pages et al., 2009; Tosolini et al., 2011). CD8+ cytotoxic T cells are the primary participants driving the adaptive immune response against cancer and executing a tumor-specific immune response; therefore, CD8+ cytotoxic T cells are the primary endpoints of immunotherapy (Spitzer et al., 2017; Ostroumov et al., 2018). On the one hand, activated CD4+ T cells secrete various cytokines, such as IFN-γ and IL-2 (Kershaw et al., 2013; Farhood et al., 2019); on the other hand, CD4+ T cells promote the costimulatory molecules and cytokine expressions of dendritic cells, all of which contribute to CD8+ T-cell activation (Gottschalk et al., 2015). Importantly, CD4+ Th1 cells (expressing IL-2 and IFN-γ) promote the cytotoxic immune response, and CD4+ Th2 cells (expressing IL-4 and IL-10) promote the humoral immune response and limit the cytotoxic immune response (Jankovic et al., 2001). CD28, a co-stimulatory molecule required for T-cell activation, is another factor involved in CD8+ cytotoxic T-cell activation (Schwartz, 1992). In the present study, CTP enhanced the levels of IFN-γ and suppressed the levels of IL-4, suggesting an increase in the Th1/Th2 ratio (Cortés et al., 2017; Yang and Zhou, 2019). CTP enhances the levels of TLR4 and TLR5 in ApcMin/+ mice, indicating an enhanced tumor killing response mediated by T cells (Brackett et al., 2016; Farrokhi et al., 2019). CTP not only enhanced the activation of T cells (CD3e+CD28+) but also increased the number of NK cells (CD3eNK1.1+) in the peripheral blood of ApcMin/+ mice. As non-specific killer cells, NK cells can promote specific immune responses or directly kill target cells via antibody-dependent pathways. A decrease in the percentage of NK cells in the peripheral blood usually leads to a high incidence of tumors (Vivier et al., 2012; Panda et al., 2017). In CTP-treated ApcMin/+ mice, the enhanced IL-2 and IL-12 levels were confirmed, indicating the promotion of T-cell and NK-cell activation (Carballido et al., 2012; Yan et al., 2018), and promotion of Th1 cells’ differentiation (Yan et al., 2018). The increase in IgG and reduction in TGF-β after CTP administration further confirmed the activation of NK cells in ApcMin/+ mice (Viel et al., 2016; Bournazos and Ravetch, 2017), which is also consistent with the findings of our previous study (Li et al., 2020). The inhibitory effect of CTP on CRC is partially linked to the promotion of the tumor immune killing response in ApcMin/+ mice, especially the activation of T cells and NK cells. CTP reduces the levels of PD-1, PD-L1, and CTLA4 in ApcMin/+ mice, which have been confirmed to regulate the immune reactivity of tumor cells (Sansom, 2000; de Vries et al., 2016), and antibodies against PD-1 and PD-L1 have
been successfully used for tumor therapy (Sunshine and Taube, 2015). The blockade of CTLA-4 and PD-1/PD-L1 promotes the proliferation of CD8+ T cells and the expression of IL-2 (Spranger et al., 2014), and the increase of IL-2 expression reverses the T-cell inhibition caused by PD-1 and its ligands (Carter et al., 2002). The activation of NF-κB signaling is a key step for inducing IL-2 gene transcription in T cells. Moreover, the co-stimulatory signaling from NFAT1 and the calcium influx of T cells results in increased IL-2 and IL-2 receptors (Clavijo and Frauwirth, 2012; Lee et al., 2018). CTP strongly enhanced the activation of NFAT1 and NF-κB p65 signaling in ApcMin/+ mice. The activation of NFAT1 and NF-κB signaling promotes the activation and differentiation of CD8+ T cells and helps in maintaining the activity of CD8+ T cells (Clavijo and Frauwirth, 2012; Lee et al., 2018). The inhibitory effect of CTP on CRC is due to promoting the immune function related to the IL-2-associated signaling pathway.

The present study has certain limitations. Accordingly, thymosin promotes T-cell maturation by increasing IL-7 synthesis (Knutsen et al., 1999), and thymosin alpha 1 increases major histocompatibility complex class-1, antagonized dexamethasone-induced apoptosis of CD4+CD8+ cells (Baumann et al., 2000). Although our present results confirmed the inhibition effect on CRC of CTP associated with T cells, the detailed mechanism of its differentiation remains to be investigated in a future study. Second, as a clinical drug, the anti-CRC effect of CTP in ApcMin/+ mice was confirmed, which requires follow-up clinical verification.

Altogether, CTP can inhibit the development of CRC in ApcMin/+ mice, which is related to intestinal microbiota changes and immune response regulation. Our data provide a reference for CTP as a therapeutic drug or combination drug used in clinical CRC treatment.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institution Animal Ethics Committee of Jilin University.

AUTHOR CONTRIBUTIONS

LL, CZ, and FK accomplished most of the assays and the analysis. Y-CL, CW, and SC contributed to the preliminary screening and assessment of drug efficacy. H-YT, YL, and DW contributed to the direction, analysis of the data, and writing of the manuscript. All the authors read and approved the final manuscript.

FUNDING

This work was supported by the Science and Technology Development Project of Jilin Province, China (20210401088YY); the Construction Project of Emergency Reserve of Traditional Chinese Medicine Prescriptions for Major Epidemic Prevention and Control of Jilin Province, China; and the Science and Technology Research Project of Education Department of Jilin Province, China (JJKH20211227KJ).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.898906/full#supplementary-material
Syed Khaja, A. S., Toor, S. M., El Salhat, H., Ali, B. R., and Elkord, E. (2017). Intratumoral FoxP3(+)/Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front. Immunol. 8, 619. doi:10.3389/fimmu.2017.00619

Tarashi, S., Siadat, S. D., Ahmadi Badi, S., Zali, M., Biassoni, R., Ponzoni, M., et al. (2019). Gut Bacteria and Their Metabolites: Which One Is the Defendant for Colorectal Cancer? Microorganisms 7 (11), 34. doi:10.3390/microorganisms7110561

Tosolini, M., Kirilovsky, A., Mlecnk, B., Fredriksen, T., Mauger, S., Bindea, G., et al. (2011). Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer. Cancer Res. 71 (4), 1263–1271. doi:10.1158/0008-5472.can-10-2907

Viel, S., Marçais, A., Guimaraes, F. S., Loffus, R., Rabilloud, J., Grau, M., et al. (2016). TGF-β Inhibits the Activation and Functions of NK Cells by Repressing the mTOR Pathway. Sci. Signal. 9 (415), ra19. doi:10.1126/scisignal.aad1884

Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., and Brossay, L. (2012). Targeting Natural Killer Cells and Natural Killer T Cells in Cancer. Nat. Rev. Immunol. 12 (4), 239–252. doi:10.1038/nri3174

Wang, X., Chan, A. T., Slattery, M. L., Chang-Claude, J., Potter, J. D., Gallinger, S., et al. (2018). Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-inflammatory Drugs on Colorectal Cancer Risk. Cancer Res. 78 (16), 4790–4799. doi:10.1158/0008-5472.can-18-0326

Yamaoka, Y., Suhiryo, Y., Hashimoto, S., Hoshida, T., Fujimoto, M., Watanabe, M., et al. (2018). Fusobacterium Nucleatum as a Prognostic Marker of Colorectal Cancer in a Japanese Population. J. Gastroenterol. 53 (4), 517–524. doi:10.1007/s00535-017-1382-6

Yan, J., Smyth, M. J., and Teng, M. W. L. (2018). Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb Perspect. Biol. 10 (7), a028530. doi:10.1101/cshperspect.a028530

Yang, Y., and Zhou, Y. (2019). Shashen-Maidong Decoction-Mediated IFN-γ and IL-4 on the Regulation of Th1/Th2 Imbalance in RP Rats. Biomed. Res. Int. 2019, 6012473. doi:10.1155/2019/6012473

Zeinelin, M., and Neufeld, K. L. (2013). More Than Two Decades of Apc Modeling in Rodents. Biochim. Biophys. Acta 1836 (1), 80–89. doi:10.1016/j.bbagrm.2013.01.001

Zeng, F. L., Xiao, Z., Wang, C. Q., Jiang, Y., Shan, J. L., Hu, S. S., et al. (2019). Clinical Efficacy and Safety of Synthetic Thymic Peptides with Chemotherapy for Non-small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials Following the PRISMA Guidelines. Int. Immunopharmacol 75, 105747. doi:10.1016/j.intimp.2019.105747

Zhang, H., Hui, D., Li, Y., Xiong, G., and Fu, X. (2019). Canmei Formula Reduces Colitis-Associated Colorectal Carcinogenesis in Mice by Modulating the Composition of Gut Microbiota. Front. Oncol. 9, 1149. doi:10.3389/fonc.2019.01149

Zhang, Z., Tang, H., Chen, P., Xie, H., and Tao, Y. (2019). Demystifying the Manipulation of Host Immunity, Metabolism, and Extraintestinal Tumors by the Gut Microbiome. Signal. Transduct Target. Ther. 4, 41. doi:10.1038/s41392-019-0074-5

Zhou, B., Yuan, Y., Zhang, S., Guo, C., Li, X., Li, G., et al. (2020). Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract. Front. Immunol. 11, 575. doi:10.3389/fimmu.2020.00575

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Zhao, Kong, Li, Wang, Chen, Tan, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.